Fibroblast growth factor receptor-3 in urothelial tumorigenesis

Urologic Oncology: Seminars and Original Investigations

Volumn 31, Issue 3, 2013, Pages 303-311

  Iyer, Gopa ^a,b   Milowsky, Matthew I ^c  

^a MEMORIAL SLOAN KETTERING CANCER CENTER   (United States)

^b WEILL CORNELL MEDICAL COLLEGE   (United States)

^c UNIVERSITY OF NORTH CAROLINA SCHOOL OF MEDICINE   (United States)

Author keywords

FGFR3; Fibroblast growth factor receptor 3; Transitional cell carcinoma; Urothelial cancer

Indexed keywords

1 TERT BUTYL 3 [6 (3,5 DIMETHOXYPHENYL) 2 (4 DIETHYLAMINOBUTYLAMINO)PYRIDO[2,3 D]PYRIMIDIN 7 YL]UREA; 3 [4 METHYL 2 (2 OXO 3 INDOLINYLMETHYLIDENYL) 3 PYRROLYL]PROPIONIC ACID; AZD 4547; BGJ 398; DOVITINIB; FIBROBLAST GROWTH FACTOR RECEPTOR 1; FIBROBLAST GROWTH FACTOR RECEPTOR 2; FIBROBLAST GROWTH FACTOR RECEPTOR 3; GEFITINIB; PRO 001; RABEPRAZOLE; TRASTUZUMAB; UNCLASSIFIED DRUG; VEMURAFENIB; XL 228;

ACANTHOSIS NIGRICANS; ACHONDROPLASIA; ACROCEPHALOSYNDACTYLY; BLADDER CANCER; CARCINOGENESIS; CRANIOFACIAL SYNOSTOSIS; CROUZON SYNDROME; ENZYME ACTIVATION; GENE OVEREXPRESSION; HUMAN; MOLECULARLY TARGETED THERAPY; PRIORITY JOURNAL; REVIEW; THANATOPHORIC DWARFISM; TRANSITIONAL CELL CARCINOMA;

ANTINEOPLASTIC AGENTS; CELL TRANSFORMATION, NEOPLASTIC; GENE EXPRESSION REGULATION, NEOPLASTIC; HUMANS; MUTATION; PROGNOSIS; RECEPTOR, FIBROBLAST GROWTH FACTOR, TYPE 3; RNA INTERFERENCE; URINARY BLADDER NEOPLASMS; UROTHELIUM;

EID: 84875378602     PISSN: 10781439     EISSN: 18732496     Source Type: Journal    
DOI: 10.1016/j.urolonc.2011.12.001     Document Type: Review

References (63)

1. Ferlay J., Shin H.R., Bray F., et al. Estimates of worldwide burden of cancer in 2008: GLOBOCAN 2008. Int J Cancer 2010, 127:2893-2917.
2. Jemal A., Siegel R., Ward E., et al. Cancer statistics, 2009. CA Cancer J Clin 2009, 59:225-249.
3. Dodurga Y., Tataroglu C., Kesen Z., et al. Incidence of fibroblast growth factor receptor 3 gene (FGFR3) A248C, S249C, G372C, and T375C mutations in bladder cancer genetics and molecular research. GMR 2011, 10:86-95.
4. Golka K., Wiese A., Assennato G., et al. Occupational exposure and urological cancer. World J Urol 2004, 21:382-391.
5. Pasin E., Josephson D.Y., Mitra A.P., et al. Superficial bladder cancer: An update on etiology, molecular development, classification, and natural history. Rev Urol 2008, 10:31-43.
6. Wu X.R. Urothelial tumorigenesis: A tale of divergent pathways. Nat Rev Cancer 2005, 5:713-725.
7. Koss L.G. Bladder cancer from a perspective of 40 years. J Cell Biochem 1992, 16I(Suppl):23-29.
8. Dalbagni G., Presti J., Reuter V., et al. Genetic alterations in bladder cancer. Lancet 1993, 342:469-471.
9. van Oers J.M., Adam C., Denzinger S., et al. Chromosome 9 deletions are more frequent than FGFR3 mutations in flat urothelial hyperplasias of the bladder. Int J Cancer 2006, 119:1212-1215.
10. Zhang Z.T., Pak J., Huang H.Y., et al. Role of Ha-ras activation in superficial papillary pathway of urothelial tumor formation. Oncogene 2001, 20:1973-1980.
11. Cappellen D., De Oliveira C., Ricol D., et al. Frequent activating mutations of FGFR3 in human bladder and cervix carcinomas. Nat Genet 1999, 23:18-20.
12. Wallerand H., Reiter R.R., Ravaud A. Molecular targeting in the treatment of either advanced or metastatic bladder cancer or both according to the signaling pathways. Curr Opin Urol 2008, 18:524-532.
13. Knowles M.A. Molecular subtypes of bladder cancer: Jekyll and Hyde or chalk and cheese?. Carcinogenesis 2006, 27:361-373.
14. Bakkar A.A., Wallerand H., Radvanyi F., et al. FGFR3 and TP53 gene mutations define two distinct pathways in urothelial cell carcinoma of the bladder. Cancer Res 2003, 63:8108-8112.
15. van Rhijn B.W., van Tilborg A.A., Lurkin I., et al. Novel fibroblast growth factor receptor 3 (FGFR3) mutations in bladder cancer previously identified in non-lethal skeletal disorders. European J Hum Genet EJHG 2002, 10:819-824.
16. Webster M.K., Donoghue D.J. Enhanced signaling and morphological transformation by a membrane-localized derivative of the fibroblast growth factor receptor 3 kinase domain. Mol Cell Biol 1997, 17:5739-5747.
17. Bernard-Pierrot I., Brams A., Dunois-Larde C., et al. Oncogenic properties of the mutated forms of fibroblast growth factor receptor 3b. Carcinogenesis 2006, 27. 740c7.
18. Sibley K., Fenton J.A., Dring A.M., et al. A molecular study of the t(4;14) in multiple myeloma. Br J Haematol 2002, 118. 514c20.
19. Logie A., Dunois-Larde C., Rosty C., et al. Activating mutations of the tyrosine kinase receptor FGFR3 are associated with benign skin tumors in mice and humans. Hum Mol Genet 2005, 14:1153-1160.
20. L'Hote C.G., Knowles M.A. Cell responses to FGFR3 signaling: Growth, differentiation, and apoptosis. Exp Cell Res 2005, 304:417-431.
21. Werner S., Duan D.S., de Vries C., et al. Differential splicing in the extracellular region of fibroblast growth factor receptor 1 generates receptor variants with different ligand-binding specificities. Mol Cell Biol 1992, 12:82-88.
22. Ornitz D.M., Xu J., Colvin J.S., et al. Receptor specificity of the fibroblast growth factor family. J Biol Chem 1996, 271:15292-15297.
23. Tomlinson D.C., Hurst C.D., Knowles M.A. Knockdown by shRNA identifies S249C mutant FGFR3 as a potential therapeutic target in bladder cancer. Oncogene 2007, 26:5889-5899.
24. Knowles M.A. Role of FGFR3 in urothelial cell carcinoma: Biomarker and potential therapeutic target. World J Urol 2007, 25:581-593.
25. Webster M.K., Donoghue D.J. Constitutive activation of fibroblast growth factor receptor 3 by the transmembrane domain point mutation found in achondroplasia. EMBO J 1996, 15:520-527.
26. Li E., You M., Hristova K. FGFR3 dimer stabilization due to a single amino acid pathogenic mutation. J Mol Biol 2006, 356:600-612.
27. Billerey C., Chopin D., Aubriot-Lorton M.H., et al. Frequent FGFR3 mutations in papillary noninvasive bladder (pTa) tumors. Am J Pathol 2001, 158:1955-1959.
28. van Rhijn B.W., Vis A.N., van der Kwast T.H., et al. Molecular grading of urothelial cell carcinoma with fibroblast growth factor receptor 3 and MIB-1 is superior to pathologic grade for the prediction of clinical outcome. J Clin Oncol 2003, 21:1912-1921.
29. Hernandez S., Lopez-Knowles E., Lloreta J., et al. Prospective study of FGFR3 mutations as a prognostic factor in non-muscle-invasive urothelial bladder carcinomas. J Clin Oncol 2006, 24:3664-3671.
30. Hernandez S., Lopez-Knowles E., Lloreta J., et al. FGFR3 and Tp53 mutations in T1G3 transitional bladder carcinomas: Independent distribution and lack of association with prognosis. Clin Cancer Res 2005, 11:5444-5450.
31. Matsumoto M., Ohtsuki Y., Ochii K., et al. Fibroblast growth factor receptor 3 protein expression in urothelial carcinoma of the urinary bladder, exhibiting no association with low-grade and/or non-invasive lesions. Oncol Reports 2004, 12:967-971.
32. Mhawech-Fauceglia P., Cheney R.T., Fischer G., et al. FGFR3 and p53 protein expressions in patients with pTa and pT1 urothelial bladder cancer. Eur J Surgical Oncol 2006, 32:231-237.
33. Gomez-Roman J.J., Saenz P., Molina M., et al. Fibroblast growth factor receptor 3 is overexpressed in urinary tract carcinomas and modulates the neoplastic cell growth. Clin Cancer Res 2005, 11:459-465.
34. Tomlinson D.C., Baldo O., Harnden P., et al. FGFR3 protein expression and its relationship to mutation status and prognostic variables in bladder cancer. J Pathol 2007, 213:91-98.
35. Jebar A.H., Hurst C.D., Tomlinson D.C., et al. FGFR3 and Ras gene mutations are mutually exclusive genetic events in urothelial cell carcinoma. Oncogene 2005, 24:5218-5225.
36. Lopez-Knowles E., Hernandez S., Malats N., et al. PIK3CA mutations are an early genetic alteration associated with FGFR3 mutations in superficial papillary bladder tumors. Cancer Res 2006, 66:7401-7404.
37. Cookson M.S., Herr H.W., Zhang Z.F., et al. The treated natural history of high risk superficial bladder cancer: 15-Year outcome. J Urol 1997, 158:62-67.
38. Grossman H.B., O'Donnell M.A., Cookson M.S., et al. Bacillus calmette-guerin failures and beyond: Contemporary management of non-muscle-invasive bladder cancer. Rev Urol 2008, 10:281-289.
39. Stein J.P., Lieskovsky G., Cote R., et al. Radical cystectomy in the treatment of invasive bladder cancer: Long-term results in 1,054 patients. J Clin Oncol 2001, 19:666-675.
40. Milowsky M.I., Stadler W.M., Bajorin D.F. Integration of neoadjuvant and adjuvant chemotherapy and cystectomy in the treatment of muscle-invasive bladder cancer. BJU international 2008, 102:1339-1344.
41. Sternberg C.N., Yagoda A., Scher H.I., et al. Preliminary results of M-VAC (methotrexate, vinblastine, doxorubicin, and cisplatin) for transitional cell carcinoma of the urothelium. J Urol 1985, 133:403-407.
42. von der Maase H., Hansen S.W., Roberts J.T., et al. Gemcitabine and cisplatin vs. methotrexate, vinblastine, doxorubicin, and cisplatin in advanced or metastatic bladder cancer: Results of a large, randomized, multinational, multicenter, phase III study. J Clin Oncol 2000, 18:3068-3077.
43. Yafi F.A., North S., Kassouf W. First- and second-line therapy for metastatic urothelial carcinoma of the bladder. Curr Oncol 2011, 18:e25-e34.
44. Trudel S., Stewart A.K., Rom E., et al. The inhibitory anti-FGFR3 antibody, PRO-001, is cytotoxic to t(4;14) multiple myeloma cells. Blood 2006, 107:4039-4046.
45. Martinez-Torrecuadrada J., Cifuentes G., Lopez-Serra P., et al. Targeting the extracellular domain of fibroblast growth factor receptor 3 with human single-chain Fv antibodies inhibits bladder carcinoma cell line proliferation. Clin Cancer Res 2005, 11:6280-6290.
46. Qing J., Du X., Chen Y., et al. Antibody-based targeting of FGFR3 in bladder carcinoma and t(4;14)-positive multiple myeloma in mice. J Clin Invest 2009, 119:1216-1229.
47. Druker B.J., Guilhot F., O'Brien S.G., et al. Five-year follow-up of patients receiving imatinib for chronic myeloid leukemia. New Engl J Med 2006, 355:2408-2417.
48. Hochhaus A., Druker B., Sawyers C., et al. Favorable long-term follow-up results over 6 years for response, survival, and safety with imatinib mesylate therapy in chronic-phase chronic myeloid leukemia after failure of interferon-&;α treatment. Blood 2008, 111:1039-1043.
49. Mok T.S., Wu Y.L., Thongprasert S., et al. Gefitinib or carboplatin-paclitaxel in pulmonary adenocarcinoma. New Engl J Med 2009, 361:947-957.
50. Chapman P.B., Hauschild A., Robert C., et al. Improved survival with vemurafenib in melanoma with BRAF V600E mutation. New Engl J Med 2011, 364:2507-2516.
51. Slamon D.J., Leyland-Jones B., Shak S., et al. Use of chemotherapy plus a monoclonal antibody against HER2 for metastatic breast cancer that overexpresses HER2. New Engl J Med 2001, 344:783-792.
52. Bang Y.J., Van Cutsem E., Feyereislova A., et al. Trastuzumab in combination with chemotherapy versus chemotherapy alone for treatment of HER2-positive advanced gastric or gastro-esophageal junction cancer (ToGA): A phase 3, open-label, randomized controlled trial. Lancet 2010, 376:687-697.
53. Trudel S., Ely S., Farooqi Y., et al. Inhibition of fibroblast growth factor receptor 3 induces differentiation and apoptosis in t(4;14) myeloma. Blood 2004, 103:3521-3528.
54. Miyake M., Ishii M., Koyama N., et al. 1-tert-butyl-3-[6-(3,5-dimethoxy-phenyl)-2-(4-diethylamino-butylamino)-pyr ido[2,3-d]pyrimidin-7-yl]-urea (PD173074), a selective tyrosine kinase inhibitor of fibroblast growth factor receptor-3 (FGFR3), inhibits cell proliferation of bladder cancer carrying the FGFR3 gene mutation along with up-regulation of p27/Kip1 and G1/G0 arrest. J Pharmacol Exp Therapeut 2010, 332:795-802.
55. Lamont F.R., Tomlinson D.C., Cooper P.A., et al. Small molecule FGF receptor inhibitors block FGFR-dependent urothelial carcinoma growth in vitro and in vivo. Br J Cancer 2011, 104:75-82.
56. Lee S.H., Lopes de Menezes D., Vora J., et al. In vivo target modulation and biological activity of CHIR-258, a multitargeted growth factor receptor kinase inhibitor, in colon cancer models. Clin Cancer Research 2005, 11:3633-3641.
57. Lopes de Menezes D.E., Peng J., Garrett E.N., et al. CHIR-258: A potent inhibitor of FLT3 kinase in experimental tumor xenograft models of human acute myelogenous leukemia. Clin Cancer Res 2005, 11:5281-5291.
58. Sarker D., Molife R., Evans T.R., et al. A phase I pharmacokinetic and pharmacodynamic study of TKI258, an oral, multitargeted receptor tyrosine kinase inhibitor in patients with advanced solid tumors. Clin Cancer Res 2008, 14:2075-2081.
59. Angevin E., Lopez J.A., Pande A., et al. TKI258 (dovitinib lactate) in metastatic renal cell carcinoma (mRCC) patients refractory to approved targeted therapies: A phase I/II dose finding and biomarker study. J Clin Oncol 2009, 27:15s. [Abstract 3563].
60. Al-Ahmadie H.A., Iyer G., Janakiraman M., et al. Somatic mutation of fibroblast growth factor receptor-3 (FGFR3) defines a distinct morphological subtype of high-grade urothelial carcinoma. Journal Pathol 2011, 224:270-279.
61. Konety B.R. Molecular markers in bladder cancer: A critical appraisal. Urol Oncol 2006, 24:326-337.
62. Steiner G., Schoenberg M.P., Linn J.F., et al. Detection of bladder cancer recurrence by microsatellite analysis of urine. Nat Med 1997, 3:621-624.
63. van Rhijn B.W., Lurkin I., Chopin D.K., et al. Combined microsatellite and FGFR3 mutation analysis enables a highly sensitive detection of urothelial cell carcinoma in voided urine. Clin Cancer Res 2003, 9:257-263.